Twelve (18%) patients had KRAS mutation, two patients were EGFR mutation‐positive (3%), one patient had a BRAF mutation (2%) and no patient had lung cancer that was ALK mutation‐positive. This evidence concerns the gene KRAS and lung carcinoma.